EVALUATING A NOVEL ROSACEA TREATMENT SYSTEM CONTAINING A CLEANSER, METRONIDAZOLE, HYDRATING COMPLEXION CORRECTOR, AND SUNSCREEN

INTRODUCTION

Rosacea is a chronic, disfiguring dermatologic disease that typically affects middle-aged women. The signs and symptoms of rosacea can include flushing, redness, irritation, andtelangiectasia. The condition often leads to emotional distress and self-consciousness. The mainstay of treatment for rosacea includes avoidance of disease triggers, topical medications, and oral antibiotics. Despite these interventions, many patients continue to experience symptoms.

A new rosacea treatment system has been developed that addresses the problems posed by rosacea disease to sensitize, soothe, and hydrate the skin while simultaneously eliminating the need to combine multiple products into a single regimen. This system incorporates metronidazole, a known rosacea therapeutic, into a comprehensive approach to skin health. The system is comprised of four products: a rosacea cleanser (2% salicylic acid, 0.75% benzoyl peroxide, +1% aspirin; 1% salicylic acid +4% citric acid), a rosacea treatment system (20% niacinamide +5% niacinamide +30% zinc oxide +0.75% metronidazole), a rosacea skin balancing product (1% salicylic acid +1% salicylic acid +1% salicylic acid +1% salicylic acid), and an SPF 30 sunscreen (Neutrogena) e.

In order to evaluate the clinical benefits of the rosacea treatment system, the system as a whole was compared to metronidazole + the standard skin care regimen. The rosacea treatment system as a whole consists of a rosacea cleanser (2% salicylic acid, 0.75% benzoyl peroxide, +1% aspirin; 1% salicylic acid +4% citric acid), a rosacea treatment system (20% niacinamide +5% niacinamide +30% zinc oxide +0.75% metronidazole), a rosacea skin balancing product (1% salicylic acid +1% salicylic acid +1% salicylic acid +1% salicylic acid), and an SPF 30 sunscreen (Neutrogena) e.

METHODS

Study design

– Investigator-blinded, parallel group study in single center

Main inclusion criteria

– Adult females
– Scales used in assessments.
– Participation in an investigational drug or device study in preceding 30 days

Main exclusion criteria

– Systolic blood pressure >160 mmHg or diastolic blood pressure >90 mmHg
– History of any facial skin condition/disease that might interfere with diagnosis or evaluation
– Participation in an investigational drug or device study in preceding 30 days
– Participation in an investigational drug or device study in preceding 30 days

Evaluations

– Mildness
– Moderate
– Severe

Scales used in assessments.

– Improvement in redness (25-49%)
– Improvement in redness (50-74%)
– Improvement in redness (75-95%)
– Improvement in redness (95-100%)

REFERENCES


